Trial Profile
An Open-label Long-Term Safety and Efficacy Extension Study in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Previously Enrolled in UX007 or Triheptanoin Studies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2023
Price :
$35
*
At a glance
- Drugs Triheptanoin (Primary)
- Indications Lipid metabolism disorders; VLCAD deficiency
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ultragenyx Pharmaceutical
- 01 Sep 2023 Results assessing the long-term safety/efficacy of triheptanoin in patients with LC-FAODs published in the Journal of Inherited Metabolic Disease
- 06 Oct 2020 Status changed from active, no longer recruiting to completed.
- 21 Aug 2020 Planned End Date changed from 1 Sep 2021 to 1 Oct 2020.